Up to 105 Japanese men will be enrolled at 11 sites, with data aimed at supporting a future marketing authorisation ...

For prostate biopsy planning, multiparametric MRI has relatively low specificity particularly for PI-RADS 3 and PI-RADS 4 ...

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today announces that the first patient has been dosed in the ...

A molecular imaging tool developed by researchers at the University of California’s two nationally ranked medical centers, UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer ...

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in ...

The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer. The FDA has approved ...

A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy. This is an ASCO Meeting Abstract from the 2024 ASCO ...

Reston, VA—In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...